← Back to Clinical Trials
Recruiting NCT07063914

NCT07063914 Stratified-Care School-Based Intervention for Adolescent Suicidal Ideation

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07063914
Status Recruiting
Phase
Sponsor Universidad de los Andes, Chile
Condition Suicidal Ideation
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2025-06-25
Primary Completion 2025-12-31

Eligibility & Interventions

Sex All sexes
Min Age 14 Years
Max Age 18 Years
Study Type INTERVENTIONAL
Interventions
Reframe-IT and CARIBOU

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2025-06-25 with a primary completion date of 2025-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Background. Suicidal ideation and depressive symptoms are highly prevalent among adolescents, with suicide representing a leading cause of death in this age group worldwide. School-based indicated prevention programs using cognitive behavioral therapy (CBT) have shown promise in addressing these mental health challenges. The Reframe-IT+ (Chile) and CARIBOU (Canada) programs are CBT-based, individually delivered interventions targeting adolescents at risk of suicide. This study aims to evaluate a culturally adapted stratified-care model using these two interventions, matched to depressive symptom severity. Methods. This is a quasi-experimental, single-arm study with pre-post assessments and follow-ups at 3, 6, 9, and 12 months. Six secondary schools with high socioeconomic vulnerability in Santiago, Chile, will participate. Students with suicidal ideation and mild/moderate depressive symptoms (PHQ-9 \< 20) will be offered Reframe-IT+, while those with severe symptoms (PHQ-9 ≥ 20) will be offered CARIBOU. Primary outcomes include the acceptability of CARIBOU, feasibility of the stratified-care model, and implementation fidelity. Secondary outcomes include reductions in suicidal ideation, depression, anxiety, hopelessness, and improvements in functioning, quality of life, behavioral activation, emotional regulation, and problem-solving skills. Discussion. This protocol addresses the need for scalable, culturally sensitive interventions for adolescent suicide prevention in school settings. By evaluating both the process and early outcomes of a stratified-care approach, this study will generate valuable evidence to inform future large-scale effectiveness trials and policy development in adolescent mental health.

Eligibility Criteria

Inclusion Criteria: * Inclusion Criteria for Educational Institutions * Located in Santiago, Chile. * Secondary education level (grades I-IV Medio). * Coeducational schools. * At least two classes per grade level in secondary education. * A minimum of 30 students per class. * Socioeconomic vulnerability level of ≥ 50%, as measured by the School Vulnerability Index (Índice de Vulnerabilidad Escolar - IVE-SINAE), which includes factors such as parental education and total household income. Inclusion Criteria for Students * Enrolled in grades I, II, or III Medio. * Suicidal ideation within the past month, defined as a score ≥ 3 on the Columbia-Suicide Severity Rating Scale (C-SSRS). * For the Reframe-IT+ program: mild or moderate depressive symptoms, defined as a PHQ-9 score \< 20. * For the CARIBOU program: severe depressive symptoms, defined as a PHQ-9 score ≥ 20. Exclusion Criteria: * Exclusion Criteria for Students * Participation in a structured suicide prevention program (Reframe-IT+) during 2024. * Severe psychotic symptoms, such as perceptual disturbances or delusional ideas, assessed during the eligibility interview. * Suicide attempt(s) in the past three months, assessed during the eligibility interview.

Contact & Investigator

Central Contact

Jorge E Gaete, MD, PhD

✉ jgaete@uandes.cl

📞 +56940245650

Principal Investigator

Jorge E Gaete, MD. PhD.

STUDY DIRECTOR

Universidad de los Andes, Chile

Frequently Asked Questions

Who can join the NCT07063914 clinical trial?

This trial is open to participants of all sexes, aged 14 Years or older, up to 18 Years, studying Suicidal Ideation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07063914 currently recruiting?

Yes, NCT07063914 is actively recruiting participants. Contact the research team at jgaete@uandes.cl for enrollment information.

Where is the NCT07063914 trial being conducted?

This trial is being conducted at Santiago, Chile.

Who is sponsoring the NCT07063914 clinical trial?

NCT07063914 is sponsored by Universidad de los Andes, Chile. The principal investigator is Jorge E Gaete, MD. PhD. at Universidad de los Andes, Chile. The trial plans to enroll 60 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology